I-Mab to seek ap­proval of pe­di­atric growth hor­mone de­fi­cien­cy drug in Chi­na next year af­ter PhI­II win

I-Mab Bio­phar­ma said Thurs­day that its long-act­ing, re­com­bi­nant growth hor­mone can­di­date met the pri­ma­ry end­point in a Phase III tri­al, set­ting the stage for its first BLA fil­ing in Chi­na.

The biotech un­veiled topline da­ta in its first-half earn­ings re­port, say­ing a once-week­ly dose of ef­tan­so­ma­t­ropin al­fa was non-in­fe­ri­or to dai­ly in­jec­tions of No­vo Nordisk’s growth hor­mone, Norditropin. Ef­tan­so­ma­t­ropin al­fa works by stim­u­lat­ing pro­duc­tion of growth fac­tor IGF-1 in the liv­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER